Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is well-positioned for growth in the rapidly evolving field of personalized cancer treatments, leveraging its strong partnerships with biopharmaceutical companies and a cash position of $261.3 million. Their success in securing Medicare coverage for their lung cancer test and efforts to expand coverage for other types of cancer reflect their potential for growth and profitability in the future. With their advanced technology and strong intellectual property strategy, Personalis is poised to capture a significant share of the estimated $35 billion market in this area.

Bears say

Personalis is anticipating growth in their biopharma and clinical diagnostics revenues, but investors should be wary of the volatility of budgets and ordering patterns with pharma companies. Additionally, the company's cross-licensing IP strategy with Myriad Genetics highlights potential IP risks they face in the ultra-sensitive MRD testing market. Furthermore, Tempus AI's financial situation raises concerns for their ability to generate enough revenue for future profitability.

Personalis Inc (PSNL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.